Abstract
Present-day is developing in many fields. Many pathological processes are better understood, including carcinogenesis. Consequently, the failure of pharmacotherapy aimed at cancerous diseases is becoming explainable. At the same time, new anticancer drugs continue to be introduced. Anthracycline antibiotics are a well-known and widely used group of anticancer drugs. However, in addition to their efficiency they demonstrate severe side effects compounded by the appearance of resistant cells. Therefore, the search for new anthracycline derivatives with improved pharmacodynamic properties and fewer adverse effects is in progress, delivering promising results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
